AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03839719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group CHX
Description: After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
Study NCT01640197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Transmax (Biotivia). 500mg (1 capsule) per day for 28 days.
Study NCT01640197 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Methyl Cellulose. 1 capsule taken once daily for 28 days.
Study NCT03909607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0.75 mg/kg
Description: Patients with moderate to severe pain will receive Ketamine at a dose of 0.75mg/kg
Study NCT03909607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 1.0 mg/kg
Description: Patients with moderate to severe pain will receive Ketamine at a dose of 1.0 mg/kg
Study NCT01198171 — intervention group
Intervention type: OTHER
Intervention: Study of Socioeconomic and Demographic Variables
Study NCT03909607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 1.5 mg/kg
Description: Patients with moderate to severe pain will receive Ketamine at a dose of 1.5 mg/kg
Study NCT02048293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanyl, Ultiva®
Description: Anesthetic induction for orotracheal intubation. Group O
Study NCT04713319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panavital
Description: In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
Study NCT04713319 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
Study NCT04745442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin + best available treatment
Description: The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.
Study NCT04745442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best available treatment
Description: The subject will be treated with the best available treatment for COVID-19.
Study NCT05331833 — intervention group
Intervention type: RADIATION
Intervention: The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT under PET-CT guidance and the control group with CTV-delineated IMRT using a random number table.
Study NCT02048293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil Laboratorios Chalver de Colombia S.A.
Description: Anesthetic induction for orotracheal intubation. Group A
Study NCT02048293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fada Remifentanilo
Description: Anesthetic induction for orotracheal intubation. Group B
Study NCT00686998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2624
Description: Oral Suspension
Study NCT00686998 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olanzapine
Description: PO BID
Study NCT00686998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02914587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTAS System
Study NCT02914587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Implantation
Study NCT01603238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LC15-0444
Description: A single oral administration of \[14C\]-LC15-0444 50 mg, containing 4.9 MBq \[14C\]. Subjects in the fasted state will receive the drug as a capsule, with 240 ml of water.
Study NCT06537778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atosiban
Description: Women in the atosiban group received i.v. atosiban (Manufacturer: Pfizer, Germany) 30 min before the surgery with a bolus dose of 6.75 mg, and the infusion was continued with an infusion rate of 18 mg/h for 3 h. The dose of atosiban was then reduced to 6 mg/h for another 21 h.
Study NCT06537778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Participants in the placebo group received only normal saline infusion for the same duration as atosiban group.
Study NCT00207636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Assisted Decision making tool
Description: The intervention consisted of access to a computer tailored decision aid designed to promote informed decision making.
Study NCT03986034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: During Venetoclax
Description: Patients with CLL/SLL will enroll on the study. Subjects will be treated at the NIH Clinical Center for the duration of the ramp-up phase of venetoclax. After the ramp-up phase is complete, subjects will be transitioned to the care of their local hematologist/oncologist and receive venetoclax monotherapy or in combination with other agent(s) at the discretion of the treating oncologist. Subjects will have the option to follow-up at the NIH every 6 months (from initiation of venetoclax) and at (suspected) progression.
Study NCT04219371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study NCT01776268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral priming
Description: Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
Study NCT02517879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community point distribution
Description: Households were invited to a central location in their community (i.e. school, church, etc) where they received their allotment of ITNs (one per sleeping space, as pre-registered ahead of study activities). Households were provided with malaria prevention messaging at the distribution. They were called up one-by-one in front of other members of the community to mitigate misrepresentation of households.
Study NCT02517879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Community point distribution
Description: Households were invited to a central location in their community (i.e. school, church, etc) where they received their allotment of ITNs (one per sleeping space, as pre-registered ahead of study activities). Households were provided with malaria prevention messaging at the distribution. They were called up one-by-one in front of other members of the community to mitigate misrepresentation of households.
Study NCT02517879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community health worker hang-up visit
Description: CHWs visited households to take stock of how many ITNs that were distributed during the distribution were hung and to hang any unhung ITNs.
Study NCT04285723 — intervention group
Intervention type: OTHER
Intervention: alpelisib
Description: Retrospective observational case-only study. There is no treatment allocation. Patients with severe or life-threatening PROS who have received alpelisib as part of a compassionate use program were invited to participate.
Study NCT01859351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-037
Study NCT01859351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-554
Study NCT01940718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Androgel
Description: T dosing will be initiated at the lowest possible level (20.25 mg testosterone = 1 pump actuation) which is expected to increase average serum T concentrations no higher than the mid-normal range (500-800 ng/dl), with respect to expected baseline measurements in our population (\~300-500 ng/dl).The T dose will be adjusted two weeks after initiation of treatment based on the measurement of serum T levels. Dosing adjustments can be made at 20.25 mg testosterone increments. The medication will be taken transdermally once daily for 3.5 months.
Study NCT02218203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject, relative to each subject's MTD)
Study NCT03498638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Therapy
Description: Couples in the intervention group will receive couples therapy for 8 weekly sessions. Each therapy session will last approximately an hour. All therapies will be conducted by the PI, Dr. Gunnur Karakurt. Dr. Karakurt is a Licenced Marriage and Family Therapist and AAMFT (American Association of Marriage and Family Therapy) approved clinical supervisor. All therapies will be conducted as a couple. Training on stress management and safety planning will be performed as individuals. There will not be any group sessions. The goal of couple therapy is to help and improve couples' capacity to regulate emotions, solve problems, and communicate through therapy with the couple together.
Study NCT03498638 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Couples in the control group will be taught safety planning, given information on local resources to help victims of violence, and will be instructed in stress and anger management strategies. Following this 8 week period, they will receive 8 weeks of couple therapy unless they choose not to.
Study NCT02218203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 0mg, 1mg, 2mg, and 4mg Lidocaine per kg of lean body mass (LBM), during each of the 4 dextromethorphan periods (placebo, low dose, medium dose, and high dose)
Study NCT03065738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tibial reduction osteotomy in total knee replacement
Description: reduction osteotomy :downsizing of tibial tray with lateralization
Study NCT05436912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.
Study NCT02218203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Dextromethorphan)
Description: 0mg Dextromethorphan
Study NCT02218203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Dextromethorphan)
Description: 0mg Dextromethorphan
Study NCT02218203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Lidocaine)
Description: 0mg/kg LBM Lidocaine
Study NCT02218203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Lidocaine)
Description: 0mg/kg LBM Lidocaine
Study NCT00735423 — intervention group
Intervention type: DEVICE
Intervention: No intervention
Description: IDE used for outcome measurement not intervention
Study NCT01573468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: Tesetaxel 27 mg/m2 orally once on Day 1 of each cycle
Study NCT01573468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo orally once on Day 1 of each cycle
Study NCT01573468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle
Study NCT01573468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle
Study NCT03847688 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation
Description: Patient receive Transcranial Magnetic Stimulation for treatment resistant depression as part of their routine care.
Study NCT04375943 — intervention group
Intervention type: DRUG
Intervention: Antidiabetic
Description: Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy
Study NCT02695472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 Milligrams NSI-189
Description: Orally Administered
Study NCT02695472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Orally administered
Study NCT02695472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered
Study NCT02695472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 Milligrams NSI-189
Description: Orally Administered
Study NCT02632864 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton arm
Description: Proton beam therapy
Study NCT03874143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Intervention for Quality of Care
Description: Does use of a specially equipped smartphone make a difference in the diagnosis and treatment by RCom of malaria, pneumonia and diarrhea in children aged 2 to 59 months
Study NCT03964935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycopene
Description: Prepared by solving lycopene powder in a solvent (ethanol: propylene glycol: water in the ratio of 50:30:20). The solution was then gelled by adding 8% hydroxypropyl cellulose (HPC). The concentration of the prepared gel equals to 2%.~After SRP, the gel delivered into periodontal pocket using insulin syringes, the therapeutic dose is about 2mg/0.1 ml.
Study NCT03964935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline HCl 1mg Oral Powder
Description: Minocycline HCl Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
Study NCT03964935 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: Used to irrigate periodontal pockets after SRP
Study NCT04345653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate (HCQ)
Description: Open-label, consecutive at-risk subjects allocation with chemoprophylaxis with HCQ.
Study NCT02856308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hairstetics hair implant device
Study NCT01449981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Twelve-Step Facilitation
Description: The iTSF condition will include review of treatment goals and overall review of progress, coping skills, real life practices, emotions/mood management, how to make changes in one's social network and discussions about how 12-step meetings can be helpful in one's recovery efforts. In addition, speakers from 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) will be invited to share their experiences and discuss myths and facts related to attendance at 12-step meetings as well as answer any questions participants have about these fellowships.
Study NCT01449981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The CBT condition will include review of progress, coping skills, group exercises, real life practice, and emotions/mood management.
Study NCT02061553 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motivation
Description: Control condition in which participants receive a single session with education on the importance of self-confidence and motivation, followed by 8 weeks of daily SMS messages with self-selected motivational statements.
Study NCT02061553 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intention
Description: Implementation intentions are created collaboratively by participants and therapists in a single 2-hour session that uses principles of brief BA (the planning of rewarding activities). BA-based implementation intentions will then be delivered daily by text for 8 weeks.
Study NCT02061553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BA-Tech
Description: Participants undergo a total of 8 sessions with a therapist. During these sessions, participants learn about the principles of BA (the translation of important life values into the planning of rewarding activities that support those values). The participants' values are explored and an activity schedule is created collaboratively by participants and therapists based on those values. Reminders to complete the scheduled activities will then be delivered by text once the schedule is made. Participants in this arm will also be monitoring their daily activities (and rating them based on enjoyment and perceived achievement) using a cell phone application.
Study NCT04481958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-PROTECT
Description: The I-PROTECT model is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes exercises based on physical and psychological principles of effective injury prevention training, specifically tailored for youth handball players, and support for developing a continuous implementation strategy. The intervention is delivered through a mobile application (the I-PROTECT GO), including modules tailored for coaches, players, club administrators, and caregivers, respectively. Coaches are introduced to the intervention in a workshop, and they will conduct the exercises with their teams during handball practice. Due to pandemic restrictions, the mobile application could not be finalized, and only the module for coaches was available.
Study NCT04509167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen Peptides
Description: Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 8 weeks.
Study NCT00418938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6mg/kg IV
Study NCT00418938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Either 5mg/kg OR 10mg/kg IV
Study NCT00418938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400mg/m\^2 IV (in the vein)
Study NCT00418938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180mg/m\^2 IV (in the vein)
Study NCT00418938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400mg/m\^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m\^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m\^2 thereafter if no significant side effects
Study NCT01454557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory Stimuli
Description: Auditory Stimuli during rest and during physical activity
Study NCT04086615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES and exercise supplemented with high BFR
Description: The BFR-NMES-Exercise training consists of 20-min sessions performed concurrently with NMES and exercise in the clinic 2x a week for a total of 18 in-clinic sessions. Using the Delfi PTS Personalized Tourniquet System for Blood Flow Restriction at 80% of LOP, the participant performs 4 exercise sets of 60 repetitions (5 seconds ea) for 5 minutes, with a 1-minute BFR deflation between sets. The standard exercise rehabilitation protocol for PFPS combines open chain and closed chain quadriceps strengthening exercises: active straight leg raises, quadriceps straightening, step up, and squats. NMES training consists of 20-minute sessions: a 2-min warm-up, 15-min work-out, and a 3-min cool down using the KneeHAB® XP Multipath stimulation system which changes the current pathways between the electrodes for preset periods within each pulse, allowing for higher stimulation intensities that maximizes muscle fibre recruitment and minimizes muscle fatigue.
Study NCT04086615 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NMES and exercise supplemented with low BFR
Description: The BFR-NMES-Exercise training consists of 20-min sessions performed concurrently with NMES and exercise in the clinic 2x a week for a total of 18 in-clinic sessions. Using the Delfi PTS Personalized Tourniquet System for Blood Flow Restriction at 20mmHG venous pressure (no blood flow restricted), the participant performs 4 exercise sets of 60 repetitions (5 seconds ea) for 5 minutes, with a 1-minute BFR deflation between sets. The standard exercise rehabilitation protocol for PFPS combines open chain and closed chain quadriceps strengthening exercises: active straight leg raises, quadriceps straightening, step up, and squats. NMES training consists of 20-minute sessions: a 2-min warm-up, 15-min work-out, and a 3-min cool down using the KneeHAB® XP Multipath stimulation system which changes the current pathways between the electrodes for preset periods within each pulse, allowing for higher stimulation intensities that maximizes muscle fibre recruitment and minimizes muscle fatigue.
Study NCT03622931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Description: Chemotherapy
Study NCT03622931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard chemotherapy
Description: Chemotherapy
Study NCT03622931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Study NCT03622931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT02282033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Moderato System
Description: The BackBeat Moderato System incorporates traditional pacing modes and algorithms to provide pacing support to patients with all conditions currently indicated for dual chamber pacing. In addition, a special pacing algorithm was developed to reduce blood pressure.
Study NCT00311168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention/treatment
Description: Device: VIP On~Device: VIP Off